Ignite Creation Date:
2024-05-05 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00413270
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2011-07-13
First Post:
2006-12-18
Brief Title:
Oral Nilotinib in Adults With Chronic Myeloid Leukemia CML in Blast Crisis Who Are Imatinib Resistant or Intolerant
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Canadian Open-label Multicenter Expanded Access Study of Oral Nilotinib in Adult Patients With Imatinib-resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis Accelerated Phase or Chronic Phase
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2011-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety of nilotinib in adult patients with imatinib-resistant or -intolerant CML-blast crisis CML-accelerated phase or CML-chronic phase when treated with nilotinib Patients will be provided access to nilotinib until the drug is available on the market
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None